{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:06:50Z","timestamp":1784102810547,"version":"3.55.0"},"reference-count":130,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense Army","doi-asserted-by":"publisher","award":["HT94252510503"],"award-info":[{"award-number":["HT94252510503"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense Army","doi-asserted-by":"publisher","award":["NIH R01CA203348"],"award-info":[{"award-number":["NIH R01CA203348"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Natural killer (NK) cells are innate lymphocytes capable of killing transformed cells without prior sensitization through direct cytolytic activity and, in an antigen-specific manner, by antibody-dependent cellular cytotoxicity (ADCC). Human NK cells mediate ADCC exclusively via the IgG Fc receptor CD16 (Fc\u03b3RIIIA), triggering degranulation and cytokine production. Multi-engager complexes, such as BiKEs, TriKEs, TetraKEs, ANKETs, and ICEs, have been developed to link CD16 to tumor antigens. However, CD16 expression can be rapidly downregulated upon NK cell activation by the proteolytic checkpoint, a disintegrin and metalloproteinase-17 (ADAM17). ADAM17 induction in NK cells occurs in response to various stimuli, including the potent activating receptor CD16 and cytokine signaling. CD16 downregulation is further exacerbated within the tumor microenvironment, significantly diminishing ADCC potency by tumor-infiltrating NK cells. Moreover, ADAM17 expression and function are upregulated in various solid tumors, leading to the release of NK cell ligands and tumor-promoting factors. Consequently, developing strategies to inhibit ADAM17 to enhance NK cell function and suppress tumor cell growth is paramount to multi-engager efficacy. This review provides an overview of NK cell biology and the role of ADAM17 in regulating NK cell function and tumor cell growth. We examine the current landscape of NK cell multi-engager complexes in clinical development and discuss emerging strategies for incorporating an ADAM17-blocking component to optimize therapeutic outcomes.<\/jats:p>","DOI":"10.3390\/cells15141269","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:29:39Z","timestamp":1784100579000},"page":"1269","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Multi-Engager Complexes Linking Natural Killer Cells to Tumor Cells and Targeting the Proteolytic Checkpoint ADAM17"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2548-7022","authenticated-orcid":false,"given":"Kate J.","family":"Dixon","sequence":"first","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1933-3887","authenticated-orcid":false,"given":"Bruce","family":"Walcheck","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2022.09.022","article-title":"Human natural killer cells: Form, function, and development","volume":"151","author":"Mace","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: Integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Abel, A.M., Yang, C., Thakar, M.S., and Malarkannan, S. (2018). Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01869"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"103261","DOI":"10.1016\/j.critrevonc.2021.103261","article-title":"Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells","volume":"160","author":"Gauthier","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annemergmed.2025.07.005","article-title":"Major Adverse Events With Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation","volume":"87","author":"Dimitrov","year":"2026","journal-title":"Ann. Emerg. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3960\/jslrt.25072","article-title":"CRS and ICANS in CAR T-cell therapy for large B-cell lymphoma","volume":"65","author":"Goto","year":"2025","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Choi, G., Shin, G., and Bae, S. (2022). Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191912366"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13287-022-02769-4","article-title":"Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer","volume":"13","author":"Kennedy","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dixon, K.J., Wu, J., and Walcheck, B. (2021). Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells. Cancers, 13.","DOI":"10.3390\/cancers13020312"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40291-021-00550-6","article-title":"Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy","volume":"25","author":"Phung","year":"2021","journal-title":"Mol. Diagn. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nikkhoi, S.K., Li, G., and Hatefi, A. (2024). Natural killer cell engagers for cancer immunotherapy. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1483884"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: An important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.smim.2014.02.007","article-title":"NK cell self tolerance, responsiveness and missing self recognition","volume":"26","author":"Shifrin","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_19","first-page":"2064","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pazina, T., Shemesh, A., Brusilovsky, M., Porgador, A., and Campbell, K.S. (2017). Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00369"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.0300-9475.2004.01398.x","article-title":"Interaction of human immunoglobulin G with CD16 on natural killer cells: Ligand clearance, FcgammaRIIIA turnover and effects of metalloproteinases on FcgammaRIIIA-mediated binding, signal transduction and killing","volume":"59","author":"Mota","year":"2004","journal-title":"Scand. J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00262-022-03299-x","article-title":"Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"72","author":"Beelen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_23","first-page":"1002","article-title":"Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2","volume":"88","author":"Golay","year":"2003","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41416-020-0934-3","article-title":"Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: Investigation of the role of cetuximab sensitivity and HPV status","volume":"123","author":"Baysal","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tian, X., Wei, F., Wang, L., Yu, W., Zhang, N., Zhang, X., Han, Y., Yu, J., and Ren, X. (2017). Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01426"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.4049\/jimmunol.151.11.6429","article-title":"Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte\/natural killer cells","volume":"151","author":"Vance","year":"1993","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/art.38337","article-title":"Fcgamma receptor IIIa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans","volume":"66","author":"Dong","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI119616","article-title":"A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease","volume":"100","author":"Wu","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/tpj.2016.51","article-title":"Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer","volume":"16","author":"Musolino","year":"2016","journal-title":"Pharmacogenom. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2008.18.0463","article-title":"Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan","volume":"27","author":"Bibeau","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jing, Y., Ni, Z., Wu, J., Higgins, L., Markowski, T.W., Kaufman, D.S., and Walcheck, B. (2015). Identification of an ADAM17 cleavage region in human CD16 (FcgammaRIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121788"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4049\/jimmunol.1301024","article-title":"ADAM17-mediated shedding of FcgammaRIIIA on human NK cells: Identification of the cleavage site and relationship with activation","volume":"192","author":"Lajoie","year":"2014","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/JLB.2MR1218-501R","article-title":"Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy","volume":"105","author":"Wu","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wang, K., Xuan, Z., Liu, X., Zheng, M., Yang, C., and Wang, H. (2022). Immunomodulatory role of metalloproteinase ADAM17 in tumor development. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1059376"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1083\/jcb.201712085","article-title":"Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells","volume":"217","author":"Srpan","year":"2018","journal-title":"J. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Pimenta, R., Arai, J., Ribeiro de Lima Brandao, L., Schmidt, P., da Silva Bortoleti, B.T., and Ferrari de Andrade, L. (2026). Insights into ectodomain shedding as a novel target in natural killer cell-based immunotherapy for cancer. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1753470"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Dixon, K.J., Hullsiek, R., Wang, S., Friess, R.R., Matson, A.W., Soignier, Y., Lenvik, A.J., Wu, J., Hart, G.T., and Felices, M. (2026). Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicity. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1714022"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e008959","DOI":"10.1136\/jitc-2024-008959","article-title":"Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells","volume":"12","author":"Matson","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1038\/s41467-025-64862-5","article-title":"A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors","volume":"16","author":"Quasem","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/17460441.2013.744745","article-title":"Novel methods and strategies in the discovery of TACE inhibitors","volume":"8","author":"Murumkar","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00262-018-2193-1","article-title":"Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNgamma production by human NK cells in the presence of antibody-bound tumor cells","volume":"67","author":"Mishra","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_46","first-page":"5507","article-title":"Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro","volume":"37","author":"Pham","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.bbamcr.2017.07.001","article-title":"The shedding protease ADAM17: Physiology and pathophysiology","volume":"1864","author":"Zunke","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/febs.16923","article-title":"The protease ADAM17 at the crossroads of disease: Revisiting its significance in inflammation, cancer, and beyond","volume":"291","author":"Saad","year":"2024","journal-title":"FEBS J."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Liu, L., Tian, E., Quan, S., Su, C., Zhou, J., Hu, S., Bian, N., Du, S., and Li, J. (2025). ADAM17 as a promising therapeutic target: From structural basis to inhibitor discovery in human diseases. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1640090"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Saad, M.I., Rose-John, S., and Jenkins, B.J. (2019). ADAM17: An Emerging Therapeutic Target for Lung Cancer. Cancers, 11.","DOI":"10.3390\/cancers11091218"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2303155120","DOI":"10.1073\/pnas.2303155120","article-title":"ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways","volume":"120","author":"Rubina","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Mishra, H.K., Ma, J., and Walcheck, B. (2017). Ectodomain Shedding by ADAM17: Its Role in Neutrophil Recruitment and the Impairment of This Process during Sepsis. Front. Cell. Infect. Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00138"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.282.5392.1281","article-title":"An essential role for ectodomain shedding in mammalian development","volume":"282","author":"Peschon","year":"1998","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.humpath.2015.02.010","article-title":"Loss of ADAM17 is associated with severe multiorgan dysfunction","volume":"46","author":"Bandsma","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1126\/science.1214400","article-title":"Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE","volume":"335","author":"Adrain","year":"2012","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/embor.2013.128","article-title":"Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation","volume":"14","author":"Christova","year":"2013","journal-title":"EMBO Rep."},{"key":"ref_59","first-page":"928","article-title":"iRHOM2 is a critical pathogenic mediator of inflammatory arthritis","volume":"123","author":"Issuree","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12135","DOI":"10.1074\/jbc.M114.624072","article-title":"The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site","volume":"290","author":"Wong","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1038\/onc.2011.522","article-title":"The unfolded protein response controls induction and activation of ADAM17\/TACE by severe hypoxia and ER stress","volume":"31","author":"Rzymski","year":"2012","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8328216","DOI":"10.1155\/2021\/8328216","article-title":"ADAM17 Mediates Hypoxia-Induced Keratinocyte Migration via the p38\/MAPK Pathway","volume":"2021","author":"Zhu","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1126\/science.2551036","article-title":"Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors","volume":"245","author":"Kishimoto","year":"1989","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/380720a0","article-title":"Neutrophil rolling altered by inhibition of L-selectin shedding in vitro","volume":"380","author":"Walcheck","year":"1996","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"ra34","DOI":"10.1126\/scisignal.2002689","article-title":"TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association","volume":"5","author":"Xu","year":"2012","journal-title":"Sci. Signal."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.4049\/jimmunol.0802770","article-title":"Regulation of mature ADAM17 by redox agents for L-selectin shedding","volume":"182","author":"Wang","year":"2009","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Arora, S., Scott, A.M., and Janes, P.W. (2025). ADAM Proteases in Cancer: Biological Roles, Therapeutic Challenges, and Emerging Opportunities. Cancers, 17.","DOI":"10.3390\/cancers17101703"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1074\/jbc.M116.746859","article-title":"Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17","volume":"292","author":"Buchanan","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"65090","DOI":"10.18632\/oncotarget.17780","article-title":"Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency","volume":"8","author":"Dosch","year":"2017","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Fabbi, M., Costa, D., Russo, D., Arenare, L., Gaggero, G., Signoriello, S., Scambia, G., Pisano, C., Colombo, N., and Losito, N.S. (2022). Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab. Diagnostics, 12.","DOI":"10.3390\/diagnostics12092118"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11010-022-04617-8","article-title":"miR-4299 inhibits tumor progression in pancreatic cancer through targeting ADAM17","volume":"478","author":"Liu","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/annonc\/mdm609","article-title":"ADAM-17 predicts adverse outcome in patients with breast cancer","volume":"19","author":"McGowan","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mds279","article-title":"ADAM-17: A novel therapeutic target for triple negative breast cancer","volume":"24","author":"McGowan","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.tranon.2019.08.003","article-title":"Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI-Mediated Anticancer Activity in NSCLC","volume":"12","author":"Yang","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Rogmans, C., Kuhlmann, J.D., Hugendieck, G., Link, T., Arnold, N., Weimer, J.P., Florkemeier, I., Rambow, A.C., Lieb, W., and Maass, N. (2021). ADAM17-A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215563"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Uribe, M.L., Marrocco, I., and Yarden, Y. (2021). EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 13.","DOI":"10.3390\/cancers13112748"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3892\/ol.2021.12709","article-title":"Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer","volume":"21","author":"Klupp","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Yonesaka, K., Takegawa, N., Satoh, T., Ueda, H., Yoshida, T., Takeda, M., Shimizu, T., Chiba, Y., Okamoto, I., and Nishio, K. (2015). Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143132"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/cam4.147","article-title":"ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC","volume":"2","author":"Kamarajan","year":"2013","journal-title":"Cancer Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00428-006-0350-y","article-title":"ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma","volume":"450","author":"Takamune","year":"2007","journal-title":"Virchows Arch."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1158\/0008-5472.CAN-13-3017","article-title":"Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30","volume":"74","author":"Schlecker","year":"2014","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cti2.1230","article-title":"NKG2D and MICA\/B shedding: A \u2018tag game\u2019 between NK cells and malignant cells","volume":"9","author":"Xing","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/febs.13669","article-title":"Caveolin-1-dependent activation of the metalloprotease TACE\/ADAM17 by TGF-beta in hepatocytes requires activation of Src and the NADPH oxidase NOX1","volume":"283","author":"Mainez","year":"2016","journal-title":"FEBS J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/cvr\/cvp176","article-title":"Oxidative stress activates ADAM17\/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion","volume":"84","author":"Brill","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Huner Yigit, M., Okcu, O., Atak, M., Karabulut, S., Yildiz, G., and Yigit, E. (2025). Modulation of Oxidative and ER Stress Pathways by the ADAM17 Inhibitor GW280264X in LPS-Induced Acute Liver Injury. Life, 15.","DOI":"10.3390\/life15121877"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"21603","DOI":"10.1074\/jbc.M115.651604","article-title":"High Glucose Up-regulates ADAM17 through HIF-1alpha in Mesangial Cells","volume":"290","author":"Li","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"33714","DOI":"10.1074\/jbc.M704041200","article-title":"Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme\/ADAM17 expression by synovial cells","volume":"282","author":"Charbonneau","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ajh\/hpu094","article-title":"Vascular induction of a disintegrin and metalloprotease 17 by angiotensin II through hypoxia inducible factor 1alpha","volume":"28","author":"Obama","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Weinberg, F., Ramnath, N., and Nagrath, D. (2019). Reactive Oxygen Species in the Tumor Microenvironment: An Overview. Cancers, 11.","DOI":"10.3390\/cancers11081191"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2567.2007.02660.x","article-title":"Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)","volume":"122","author":"Belisle","year":"2007","journal-title":"Immunology"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Rocca, Y.S., Roberti, M.P., Julia, E.P., Pampena, M.B., Bruno, L., Rivero, S., Huertas, E., Sanchez Loria, F., Pairola, A., and Caignard, A. (2016). Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00413"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2017.02.028","article-title":"IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer","volume":"145","author":"Felices","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7150\/jca.2.443","article-title":"Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells","volume":"2","author":"Jewett","year":"2011","journal-title":"J. Cancer"},{"key":"ref_98","first-page":"161","article-title":"Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma","volume":"2","author":"Lai","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","article-title":"Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition","volume":"19","author":"Wiernik","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Mishra, H.K., Dixon, K.J., Pore, N., Felices, M., Miller, J.S., and Walcheck, B. (2021). Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.711621"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/bloodadvances.2018029371","article-title":"Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL","volume":"3","author":"Felices","year":"2019","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jimmun\/vkaf036","article-title":"Natural killer cell-based immunotherapy for cancer","volume":"214","author":"Ma","year":"2025","journal-title":"J. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e011370","DOI":"10.1136\/jitc-2024-011370","article-title":"Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer","volume":"13","author":"Khaw","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.smim.2017.07.011","article-title":"Natural killer cells unleashed: Checkpoint receptor blockade and BiKE\/TriKE utilization in NK-mediated anti-tumor immunotherapy","volume":"31","author":"Davis","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Vallera, D.A., Oh, F., Kodal, B., Hinderlie, P., Geller, M.A., Miller, J.S., and Felices, M. (2021). A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer. Cancers, 13.","DOI":"10.3390\/cancers13163994"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"mAbs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","article-title":"Redirected optimized cell killing (ROCK(R)): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity","volume":"11","author":"Ellwanger","year":"2019","journal-title":"mAbs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1950264","DOI":"10.1080\/19420862.2021.1950264","article-title":"Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors","volume":"13","author":"Wingert","year":"2021","journal-title":"mAbs"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.nbt.2023.09.002","article-title":"Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells","volume":"77","author":"Giang","year":"2023","journal-title":"New Biotechnol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1038\/s41467-025-63069-y","article-title":"The bispecific innate cell engager AFM28 eliminates CD123(+) leukemic stem and progenitor cells in AML and MDS","volume":"16","author":"Schmitt","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"100783","DOI":"10.1016\/j.xcrm.2022.100783","article-title":"Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant","volume":"3","author":"Demaria","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/1750743X.2026.2688683","article-title":"Recent advances in bispecific natural killer cell engagers for cancer immunotherapy","volume":"18","author":"Thalji","year":"2026","journal-title":"Immunotherapy"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: Final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a Bispecific CD30\/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30(+) Malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1158\/1078-0432.CCR-24-1913","article-title":"A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas","volume":"31","author":"Kim","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-24-1991","article-title":"First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors","volume":"31","author":"Saavedra","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.4110\/in.2024.24.e34","article-title":"Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46","volume":"24","author":"Shin","year":"2024","journal-title":"Immune Netw."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.bmc.2008.11.067","article-title":"Current perspective of TACE inhibitors: A review","volume":"17","author":"DasGupta","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd2092","article-title":"Targeting proteases: Successes, failures and future prospects","volume":"5","author":"Turk","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ncprheum0797","article-title":"Drug insight: Tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis","volume":"4","author":"Moss","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Richards, F.M., Tape, C.J., Jodrell, D.I., and Murphy, G. (2012). Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040597"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-14-1040","article-title":"A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways","volume":"14","author":"Sabol","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/bjc.2015.163","article-title":"Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells","volume":"112","author":"Caiazza","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"117605","DOI":"10.1016\/j.biopha.2024.117605","article-title":"Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells","volume":"180","author":"Saha","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"101265","DOI":"10.1016\/j.tranon.2021.101265","article-title":"Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells","volume":"15","author":"Saha","year":"2022","journal-title":"Transl. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1269\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:35:44Z","timestamp":1784100944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":130,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cells15141269"],"URL":"https:\/\/doi.org\/10.3390\/cells15141269","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}